Business

Business Area-Medifood

Market Entry Strategy of Medifood
CorriX has confirmed the MOA (Mechanism of Action) of TFα antibody production in the body through human study on 140 healthy adults in Germany. Furthermore, CorriX plans to conduct a human application test on cancer patients to confirm the increase in TFα antibodies through consumption. TE BioS will advance to become a global medical food brand.

  • 1. Human application study on cancer patients

    CorriX plans to conduct a human application study on cancer patients to confirm safety and increase in TFα antibodies

  • 2. Publication in international academic journals

    CorriX plans to publish a paper in an international academic journal on the safety and efficacy results of increasing TFα antibodies confirmed through clinical trials targeting cancer patients.
    Human application study

  • 3. Dominating the domestic cancer patient meal market

    CorriX will advance to become a specialized domestic brand of medical food for cancer patients based on the efficacy data on the increase in TFα antibodies in cancer patients from CorriX.

  • 4. Combination immunotherapy for cancer

    Building on CorriX’s efficacy data demonstrating increased TFα antibody levels in cancer patients, we will collaborate with global pharmaceutical companies to develop combination therapies, paving the way for innovative cancer treatment options.

Anticipated Outcomes of Developing Medical Foods for Cancer Patients
  • Securing scientific evidence on the safety of CorriX and the production of TFα antibodies in cancer patients
  • Securing reliability of medical food through publication of journals and appealing differentiated factors and efficacy to consumers
  • Developing nutritional supplements for cancer patients and establishing a global medical food brand specializing in cancer patients
  • Joint research on combination anticancer treatment with global pharmaceutical companies